FDA clinical trials
In the past months we’ve seen the approval of several drugs with limited data. Possibly this is the ‘natural’ consequence of both the Fast Track Designation and the Adaptative Pathway solutions that have been accepted.
In the past months we’ve seen the approval of several drugs with limited data. Possibly this is the ‘natural’ consequence of both the Fast Track Designation and the Adaptative Pathway solutions that have been accepted.